Skip to content
drillr.ai

ABEO

Abeona Therapeutics Inc.

NASDAQ · USHealthcareBiotechnology
$6.48-7.43%

Price as of Jul 20, 2026

ABEO news

Abeona Therapeutics Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CLEVELAND, July 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On June 30, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the ag

    Globe Newswire ·

  2. Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

    CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in June 2026: * 2026 Jefferies Global Healthcare Conference: Fireside chat at 3:10 PM ET on Thursday, June 4, 2026 and investor meetings. * Goldman Sachs 47(th) Annual Global Healthcare Conference 2026: Investor meetings on Monday, June 8, 2026. A live webcast of the fireside chat can be accessed on the Investor

    Globe Newswire ·

  3. Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update

    - Three patients treated with ZEVASKYN(®) in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast -  - In-licensed radically novel engineered T-cell technology with game changing potential in the field of solid tumors; ophthalmology programs deprioritized - - $168.3M in cash, cash equivalents and short-term investments as of March 31, 2026 - - Webcast today at 8:30am ET - CLEVELAND, May 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) to

    Globe Newswire ·

  4. Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates

    - First ZEVASKYN(®) commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 - CLEVELAND, March 17, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2025 and recent operational progress. “2026 is about building a steady cadence of biopsies and treatments,” said Vish Seshadri, Chief Exec

    Globe Newswire ·

  5. Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

    CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company’s launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Following the optimization of a release assay in 2025, ZEVASKYN commercial launch activities commenced in the fourth quarter, with the

    Globe Newswire ·